AstraZeneca’s rare disease unit overcomes FDA snub to expand Ultomiris in NMOSD

Nearly five years after an FDA approval for Soliris in neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s follow-on C5 drug Ultomiris has entered the rare neurological disease, as well.